Psych and neu­ro R&D notch a win as BioX­cel gets FDA ap­proval for schiz­o­phre­nia, bipo­lar dis­or­der-re­lat­ed ag­i­ta­tion

While drug de­vel­op­ment for neu­ro and psy­chi­a­try are no­to­ri­ous­ly slug­gish, the fields took a step for­ward Wednes­day with the lat­est FDA ap­proval.

BioX­cel Ther­a­peu­tics, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER